Effective treatment of a patient with stage IV ovarian cancer: A case report

Huang,Zhen; Yan,Hua; Chavan,Devendra; Yuan,Zeng; Yang,Xingsheng; Zhang,Youzhong; Song,Kun; Kong,Beihua

doi:10.3892/ol.2017.7285

January-2018 Volume 15 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2018 Volume 15 Issue 1

Full Size Image

Case Report

Effective treatment of a patient with stage IV ovarian cancer: A case report

Authors:
- Zhen Huang
- Hua Yan
- Devendra Chavan
- Zeng Yuan
- Xingsheng Yang
- Youzhong Zhang
- Kun Song
- Beihua Kong
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Spleen and Stomach Diseases, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250012, P.R. China
Pages: 588-591
|
Published online on: October 30, 2017

https://doi.org/10.3892/ol.2017.7285
Expand metrics +

Abstract

The present case report describes a patient with stage IV ovarian cancer who survived for 9 years without achieving a complete remission since the first relapse. The patient's long‑term survival may be ascribed to the slow growth of the cancer cells, limited metastasis and favorable responses to the treatments received. The patient manifested initially with malignant pleural effusion and was not able to tolerate surgical treatment. However, the disease was well‑controlled using various treatments, including neoadjuvant chemotherapy, interval cytoreductive surgery and post‑operative long‑term chemotherapy. Management of ovarian cancer is most effective when tailored to the individual needs of the patient, maximizing its efficacy and prolonging the patient's survival rate. The present case may offer useful insight into the clinical management of stage IV ovarian cancer

View Figures

View References

1	Jayson GC, Kohn EC, Kitchener HC and Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014. View Article : Google Scholar : PubMed/NCBI
2	Narod S: Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol. 13:255–261. 2016. View Article : Google Scholar : PubMed/NCBI
3	Davidson B and Tropé CG: Ovarian cancer: Diagnostic, biological and prognostic aspects. Womens Health (Lond). 10:519–533. 2014. View Article : Google Scholar : PubMed/NCBI
4	van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J and Pecorelli S: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological cancer cooperative group of the European organization for research and treatment of cancer. N Engl J Med. 332:629–634. 1995. View Article : Google Scholar : PubMed/NCBI
5	Redman CW, Warwick J, Luesley DM, Varma R, Lawton FG and Blackledge GR: Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol. 101:142–146. 1994. View Article : Google Scholar : PubMed/NCBI
6	Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH and Small JM; Gynecologic Oncology Group, : Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 351:2489–2497. 2004. View Article : Google Scholar : PubMed/NCBI
7	Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, et al: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 363:943–953. 2010. View Article : Google Scholar : PubMed/NCBI
8	Colombo N: Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: New data from the randomized OVA-301 study. Int J Gynecol Cancer. 21 Suppl 1:S12–S16. 2011. View Article : Google Scholar : PubMed/NCBI
9	Kaye SB, Colombo N, Monk BJ, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Vergote I, et al: Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol. 22:49–58. 2011. View Article : Google Scholar : PubMed/NCBI
10	Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, et al: Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: Outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 22:39–48. 2011. View Article : Google Scholar : PubMed/NCBI
11	Rustin GJ: Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann Oncol. 22 Suppl 8:viii45–viii48. 2011. View Article : Google Scholar : PubMed/NCBI